Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2303054 | 0.85 | LTA4H (0.49) | LTA4HMAPK14NPC1RAB9ANOS3 | |
| Hydrochloric Acid SCHEMBL29857909 | 0.83 | LTA4H (0.47) | LTA4HMAPK14NPC1RAB9ANOS3 | |
| SCHEMBL9124268 | 0.78 | MET (0.42) | LTA4HMAPK14NPC1RAB9ANOS3 | |
| SCHEMBL364523 | 0.78 | S1PR4 (0.40) | LTA4HMAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16335206 | 0.78 | CHRNB2 (0.38) | NPC1RAB9ASMN1; SMN2METGRM5 | |
| SCHEMBL875218 | 0.77 | NPC1 (0.46) | LTA4HMAPK14NPC1RAB9ANOS3 | |
| SCHEMBL23794033 | 0.76 | LTA4H (0.41) | LTA4HMAPK14NPC1RAB9ANOS3 | |
| SCHEMBL10683029 | 0.76 | LTA4H (0.41) | LTA4HMAPK14NPC1RAB9ANOS3 | |
| SCHEMBL2123624 | 0.74 | LTA4H (0.54) | LTA4HMAPK14NPC1RAB9ANOS3 | |
| SCHEMBL9890 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023203174-A1 | HETEROCYCLIC CULLIN RING UBIQUITIN LIGASE COMPOUNDS AND USES THEREOF | PROXYGEN GMBH (AT) | 2023-10-26 | — | — | WO | disclosed |
| EP-2619202-A1 | PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES | Pfizer Inc (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130184294-A1 | Pyrimidones for Treatment of Potassium Channel Related Diseases | PFIZER INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2012038850-A1 | PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES | PFIZER INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184294-A1 | Pyrimidones for Treatment of Potassium Channel Related Diseases | KCNQ5, KCNQ1, KCNQ3 | LTA4H 2022/4885MAPK14 1411/4885NPC1 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.